{"id":"tak-279","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3348923","moleculeType":"Small molecule","molecularWeight":"506.30"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TAK-279 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.","oneSentence":"TAK-279 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:17.278Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07286058","phase":"PHASE3","title":"Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-03-11","conditions":"Psoriatic Arthritis","enrollment":1182},{"nctId":"NCT07108283","phase":"PHASE2","title":"A Study of Zasocitinib in Adults With Nonsegmental Vitiligo","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-11-03","conditions":"Nonsegmental Vitiligo","enrollment":200},{"nctId":"NCT06254950","phase":"PHASE2","title":"A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-03-29","conditions":"Ulcerative Colitis","enrollment":207},{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT07250802","phase":"PHASE3","title":"A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-12-04","conditions":"Plaque Psoriasis","enrollment":110},{"nctId":"NCT06671496","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-10","conditions":"Psoriatic Arthritis","enrollment":600},{"nctId":"NCT07244263","phase":"PHASE2","title":"A Study of Zasocitinib in Adults With Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-26","conditions":"Hidradenitis Suppurativa","enrollment":90},{"nctId":"NCT07403968","phase":"PHASE2","title":"A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-05-16","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT06233461","phase":"PHASE2","title":"A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-03-05","conditions":"Crohn's Disease","enrollment":268},{"nctId":"NCT06550076","phase":"PHASE3","title":"A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2024-09-04","conditions":"Plaque Psoriasis","enrollment":1950},{"nctId":"NCT06764615","phase":"PHASE2","title":"A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-05-28","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":183},{"nctId":"NCT06973291","phase":"PHASE3","title":"A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2025-07-09","conditions":"Plaque Psoriasis","enrollment":606},{"nctId":"NCT06108544","phase":"PHASE3","title":"A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-11-06","conditions":"Plaque Psoriasis","enrollment":1108},{"nctId":"NCT06323356","phase":"PHASE3","title":"A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2024-03-19","conditions":"Generalized Pustular Psoriasis, Erythrodermic Psoriasis","enrollment":18},{"nctId":"NCT06088043","phase":"PHASE3","title":"A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-11-06","conditions":"Plaque Psoriasis","enrollment":693},{"nctId":"NCT06793943","phase":"PHASE1","title":"A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-01-23","conditions":"Healthy Volunteers","enrollment":78},{"nctId":"NCT05976321","phase":"PHASE1","title":"A Study of TAK-279 in Adults With or Without Liver Damage","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-09-22","conditions":"Hepatic Impairment, Healthy Volunteers","enrollment":27},{"nctId":"NCT06111547","phase":"PHASE1","title":"A Study of TAK-279 in Healthy Chinese Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-06-24","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT06258265","phase":"PHASE1","title":"A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-04-29","conditions":"Healthy Volunteers","enrollment":120},{"nctId":"NCT05992155","phase":"PHASE1","title":"A Study of TAK-279 in Adults With or Without Kidney Problems","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-09-27","conditions":"Renal Impairment, Healthy Volunteers","enrollment":24},{"nctId":"NCT05153148","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-01-06","conditions":"Psoriatic Arthritis","enrollment":305},{"nctId":"NCT06290050","phase":"PHASE1","title":"A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-03-29","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT05995249","phase":"PHASE1","title":"A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-08-11","conditions":"Healthy Volunteers","enrollment":172},{"nctId":"NCT04999839","phase":"PHASE2","title":"Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-08-11","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":259}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zasocitinib"],"phase":"phase_3","status":"active","brandName":"TAK-279","genericName":"TAK-279","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-279 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}